Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Mario TiribelliRoberto LatagliataMassimo BrecciaIsabella CapodannoMaria Cristina MiggianoFrancesco CavazziniCristina BucelliImmacolata AttolicoSabrina Leonetti CrescenziSabina RussoMario AnnunziataFederica SoràMassimiliano BonifacioOlga MulasGiuseppina LoglisciAlessandro MaggiGianni BinottoElena CrisàAnna Rita ScortechiniAnna Paola LeporaceRosaria SancettaPamela MurganoElisabetta AbruzzeseFabio StagnoDavide RapezziDebora LuziIolanda VincelliMonica BocchiaCarmen FavaAlessandra MalatoMonica CrugnolaMichele PizzutiFrancesca LunghiSara GalimbertiMatteo DalmazzoRenato FaninEmilia ScalzulliRobin FoàAlessandra IurloGiuseppe SaglioGiorgina SpecchiaPublished in: Cancer (2023)
This observational study of almost 2000 cases of CML shows that imatinib is the frontline drug of choice in 55% of Italian patients with CP-CML, with 2G-TKIs prevalently used in younger patients and in those with no concomitant clinical conditions. Introduction of the generic formulation in 2018 seems to have fostered imatinib use.